M Kathryn Fink Sells 7,347 Shares of Stryker Co. (NYSE:SYK) Stock

Stryker Co. (NYSE:SYK) VP M Kathryn Fink sold 7,347 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

M Kathryn Fink also recently made the following trade(s):

• On Friday, September 13th, M Kathryn Fink sold 2,121 shares of Stryker stock. The shares were sold at an average price of $370.00, for a total value of $784,770.00.

Stryker Stock Performance

Shares of SYK opened at $361.29 on Thursday. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $374.63. The firm has a fifty day simple moving average of $344.08 and a 200 day simple moving average of $342.74. The stock has a market capitalization of $137.68 billion, a price-to-earnings ratio of 41.24, a PEG ratio of 2.87 and a beta of 0.91.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The company had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. During the same quarter last year, the company earned $2.54 EPS. Stryker’s revenue for the quarter was up 8.5% compared to the same quarter last year. Research analysts forecast that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.89%. Stryker’s payout ratio is 36.53%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of recent analyst reports. Wolfe Research assumed coverage on shares of Stryker in a research report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 target price for the company. BTIG Research increased their price target on Stryker from $360.00 to $374.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Stifel Nicolaus cut their price objective on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. UBS Group increased their target price on Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a report on Monday. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $378.58.

Institutional Trading of Stryker

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Stryker by 1.0% during the first quarter. Vanguard Group Inc. now owns 31,459,393 shares of the medical technology company’s stock worth $11,258,373,000 after buying an additional 309,592 shares during the last quarter. Greenleaf Trust increased its holdings in shares of Stryker by 0.6% in the first quarter. Greenleaf Trust now owns 18,596,387 shares of the medical technology company’s stock valued at $6,655,089,000 after purchasing an additional 108,080 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Stryker by 5.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,541,845 shares of the medical technology company’s stock valued at $3,755,782,000 after purchasing an additional 642,178 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Stryker by 10.4% during the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company’s stock worth $3,096,078,000 after buying an additional 813,311 shares during the period. Finally, Franklin Resources Inc. grew its stake in Stryker by 0.6% in the 4th quarter. Franklin Resources Inc. now owns 4,686,440 shares of the medical technology company’s stock valued at $1,403,401,000 after buying an additional 29,209 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.